Jim Hollingshead BVI Medical CEO Rating

BVI Medical CEO Jim Hollingshead Bio

Jim Hollingshead brings more than three decades of global leadership experience across medtech and life sciences, with a career distinguished by the successful launch and scale-up of category-defining products. Before joining BVI, Jim twice led transformative companies, achieving top market share, sustained profitable growth, and meaningful improvements in patients’ lives. As President and CEO of Insulet Corporation from 2022 to 2025, after first joining as an Independent Director, Jim drove the launch of revolutionary technologies that leapfrogged competitors and positioned Insulet as the #1 player in its category. His leadership combined product vision with commercial rigor, translating innovation into rapid market adoption.

Prior to Insulet, Jim held senior executive roles at ResMed, including President of the Sleep and Respiratory Care business, President of the Americas, Chief Strategy Officer, and President of Ventures & Initiatives. There, he led the conceptualization and launch of cloud-based offerings that redefined connected care and reshaped the industry’s competitive landscape. Jim began his career in strategy consulting, advising global organizations across multiple industries, and today serves on the Board of Vantive, a leading kidney care medtech company. He holds a BA from Stanford University and a master’s and Ph.D. from UC Berkeley.

BVI Medical CEO Jim Hollingshead At a Glance

The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at BVI Medical.

Based on 26 ratings, Jim Hollingshead ranks right above Alcon's CEO, David J. Endicott.

Overall, the CEO score has remained stable over the last 90 days.